Parallel Advisors, LLC Macrogenics Inc Transaction History

Parallel Advisors, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 May 20, 2024	BUY	$4.48 - $6.19 $0 - $0	0 New	0 $0
Q3 2023 Nov 13, 2023	BUY	$4.48 - $6.19 $0 - $0	0 New	0 $0
Q4 2022 Feb 03, 2023	BUY	$3.34 - $6.98 $70 - $146	21 New	21 $0
Q1 2020 Apr 27, 2020	SELL	$4.28 - $12.11 $1,463 - $4,141	-342 Closed	0 $0
Q4 2019 Jan 30, 2020	BUY	$7.95 - $12.27 $2,718 - $4,196	342 New	342 $4,000
Q3 2019 Nov 01, 2019	SELL	$12.44 - $17.48 $945 - $1,328	-76 Closed	0 $0
Q2 2019 Aug 05, 2019	BUY	$14.51 - $19.71 $1,102 - $1,497	76 New	76 $1,000
Q1 2019 May 01, 2019	SELL	$11.11 - $25.6 $911 - $2,099	-82 Closed	0 $0
Q4 2018 Feb 05, 2019	SELL	$11.75 - $21.42 $340 - $621	-29 Reduced 26.13%	82 $1,000
Q3 2017 Nov 15, 2017	BUY	$15.52 - $18.94 $1,722 - $2,102	111	111 $2,000

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Parallel Advisors, LLC with notifications on news.